Drug firm Ranbaxy Laboratories launched a generic version of Caduet, used for treating cardio vascular diseases, in the US market, as part of an agreement with Pfizer Inc. Caduet presently marketed by Pfizer is a fixed-dose combination of Atorvastatin-Amlodipine besylate which also contains a crystalline form of Atorvastatin. According to IMS-MAT September 2011, Caduet generated total annual sales of USD 339 million in the US.